Rocket Pharmaceuticals posts Q2 profit helped by PRV sale

Rocket Pharmaceuticals

10/08/2026 21:10

Overview
US biotech firm reported Q2 net income after KRESLADI approval and PRV sale
R&D and G&A expenses fell yr/yr due to lower headcount and commercial costs
Company ended Q2 with $283.7 mln cash, expects runway into Q2 2028

Outlook
Company expects to provide regulatory update on Danon disease program in H2 2026
Rocket anticipates commercial availability and patient onboarding for KRESLADI in Q4 2026
Company expects cash, cash equivalents and investments to fund operations into Q2 2028

Result Drivers
PRV SALE - Net income increase was helped by the $178 mln gain from sale of Priority Review Voucher after KRESLADI approval
LOWER OPERATING COSTS - R&D and G&A expenses fell yr/yr due to decreased headcount, manufacturing, and commercial costs

Company press release: ID:nBwbqxJk1a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
 
$1.08
 
Q2 Net Income
 
$123.20 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Rocket Pharmaceuticals, Inc. is $10.00, about 177% above its August 7 closing price of $3.61

Reuters Recommended Reads
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)